PRESS RELEASE 2018

The INVOcell intravaginal culture (IVC) device uses a woman’s own body as a natural incubator during fertilization and early embryo development Ferring aims to help increase access to fertility treatment by making the INVOcell IVC system a widely available option for women and their healthcare pr...

NOCDURNA is the first and only sublingual tablet for the treatment of nocturia due to nocturnal polyuria in adults who awaken at least two times per night to void.1 NOCDURNA sublingual tablets dissolve rapidly and have specific dosing designed for men and women to deliver a low and effective dose...

ZOMA-Jet 10 is a new completely needle-free delivery option available for children and adults being treated with the growth hormone, ZOMACTON 10mg ZOMACTON (somatropin) for injection is approved for 5 pediatric and 1 adult indication                                                    […]

Research collaboration aims to uncover new insights into ovarian biology and accelerate the development of personalized interventions in reproductive medicine and women’s health  Research aims to explore individual differences in women’s responses to IVF treatment, improve success rates, and...

  ZOMACTON now approved for 5 pediatric and 1 adult indication  Ferring will launch ZOMA-Jet® 10 Needle-Free Delivery System for ZOMACTON in September                                                                             […]

  New data show heat-stable carbetocin is as effective as oxytocin, the current standard of care, in preventing excessive bleeding (postpartum haemorrhage (PPH)) following vaginal birth[1] Results from the largest study conducted in prevention of PPH with nearly 30,000 women, conducted by th...

Clinical trials demonstrated an average reduction of nighttime voids of 52% in women and 43% in men relative to mean baseline (reduction of 1.5 and 1.3 voids respectively)1 NOCDURNA sublingual tablets dissolve rapidly and have specific dosing designed for men and women to deliver a low and effect...

Tuesday, June 5, 12:00-2:00 p.m., Dr. Lawrence Hookey to present “A Randomized, Assessor-Blinded, Multicenter Study Demonstrates the Efficacy and Safety of a New Ready-to-Drink Low Volume Bowel Preparation Prior to Colonoscopy” (Poster # Tu2010) Parsippany, NJ – June 5, 2018 – Today at Digestive ...

  rAd-IFN/Syn3, a novel gene therapy, is in Phase 3 development to treat high-grade non-muscle invasive bladder cancer patients, who are unresponsive to BCG therapy The US FDA has granted Fast Track and Breakthrough Therapy designations to rAd-IFN/Syn3 Ferring US will create a new oncology d...

• Rebiotix’s RBX2660 is a non-antibiotic treatment in Phase 3 development for the prevention of recurrent Clostridium difficile infection (CDI) and has the potential to be the world’s first approved human microbiome product • CDI is one of the most common healthcare-associated infections in the U...

First and only FDA-Approved, Ready-to-Drink Low-Volume Bowel Prep Parsippany, NJ – February 12, 2018 – Ferring Pharmaceuticals Inc. announced today that CLENPIQ™ (sodium picosulfate, magnesium oxide, and anhydrous citric acid) oral solution for cleansing of the colon in adults undergoing a colono...

PARSIPPANY, N.J., January 31, 2018 – Ferring Pharmaceuticals Inc. today announced that the U.S. Food and Drug Administration (FDA) has approved ZOMACTON® (somatropin) for Injection 5 mg and 10 mg recombinant human growth hormone (GH) indicated for replacement of GH in adults with GH deficiency.